CA3130513A1 - Tumor-selective combination therapy - Google Patents

Tumor-selective combination therapy Download PDF

Info

Publication number
CA3130513A1
CA3130513A1 CA3130513A CA3130513A CA3130513A1 CA 3130513 A1 CA3130513 A1 CA 3130513A1 CA 3130513 A CA3130513 A CA 3130513A CA 3130513 A CA3130513 A CA 3130513A CA 3130513 A1 CA3130513 A1 CA 3130513A1
Authority
CA
Canada
Prior art keywords
tumor
cells
lap
dnq
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3130513A
Other languages
English (en)
French (fr)
Inventor
Paul J. Hergenrother
Xiaoguang Li
Lingxiang JIANG
Yang-Xin Fu
Xiumei HUANG
David Boothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
University of Texas System
University of Illinois System
Original Assignee
University of Texas System
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Illinois System filed Critical University of Texas System
Publication of CA3130513A1 publication Critical patent/CA3130513A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3130513A 2019-03-18 2020-03-18 Tumor-selective combination therapy Pending CA3130513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
US62/819,870 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
CA3130513A1 true CA3130513A1 (en) 2020-09-24

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3130513A Pending CA3130513A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Country Status (10)

Country Link
US (1) US20220160703A1 (enExample)
EP (1) EP3942061A4 (enExample)
JP (1) JP2022525476A (enExample)
KR (1) KR20220004025A (enExample)
CN (1) CN113905763A (enExample)
AU (1) AU2020240035A1 (enExample)
BR (1) BR112021018545A2 (enExample)
CA (1) CA3130513A1 (enExample)
MX (1) MX2021011301A (enExample)
WO (1) WO2020190990A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037382T2 (hu) * 2010-09-22 2018-08-28 Univ Texas Eljárás rák kezelésére targeting NQOl alkalmazásával
PT2984184T (pt) * 2013-04-09 2021-02-24 Univ Texas Utilização de dnq ou dnq-87 em combinação com um inibidor de parp1 para o tratamento do cancro
EP3334465A1 (en) * 2015-08-12 2018-06-20 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
US11865116B2 (en) * 2016-03-24 2024-01-09 Cothera Bioscience, Inc. Treatment of cancer with TG02
CN111492245A (zh) * 2017-07-21 2020-08-04 基因泰克公司 癌症的治疗和诊断方法

Also Published As

Publication number Publication date
EP3942061A4 (en) 2022-12-14
US20220160703A1 (en) 2022-05-26
BR112021018545A2 (pt) 2021-12-14
WO2020190990A1 (en) 2020-09-24
JP2022525476A (ja) 2022-05-16
EP3942061A1 (en) 2022-01-26
KR20220004025A (ko) 2022-01-11
MX2021011301A (es) 2022-01-19
AU2020240035A1 (en) 2021-10-07
CN113905763A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
JP6719620B2 (ja) 腫瘍選択的併用療法
ES2622527T3 (es) Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
CN101888777A (zh) 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
US20220401474A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
USRE50319E1 (en) Compounds and methods for treating cancer
Sai et al. Basic and translational research on carbon-ion radiobiology
CA3130513A1 (en) Tumor-selective combination therapy
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
TW201919645A (zh) 作為免疫調節劑的磷酸鉑(phosphaplatin)化合物及其治療用途
US20240293430A1 (en) Withaferin a and immune checkpoint blocker combination therapies
CA3146792A1 (en) Combination therapy for cancer treatment
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
US20250375458A1 (en) Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases
US20210246127A1 (en) Compounds and methods targeting gper for treatment of diseases associated with calcium
EP4419209A1 (en) Combination decitabine and mps1 inhibitor therapy to prime cancer immunogenicity
EA048235B1 (ru) Соединения, модулирующие диацилглицеринкиназу
HK40031775A (en) Compounds and methods for treating cancer
HK40031775B (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240314